Myriad Genetics upgraded to Neutral from Underperform at Credit Suisse Credit Suisse upgraded Myriad Genetics to Neutral based on strong quarterly results and the Crescendo acquisition that adds diversification and accretion. Price target raised to $29 from $18.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Myriad Genetics advises prior BRACAnalysis news release be disregarded Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.